Remote Monitored Systems PLC (LON:RMS) said commercial production of anti-viral masks at its Pharm 2 Farm (P2F) subsidiary is expected to start in January 2021.
The company received notification yesterday that the production machinery is expected to undergo final acceptance testing in mid-December at the manufacturer’s premises in Spain. It will then be shipped, installed and commissioned at P2F’s Biocity premises in Nottingham.
In October, Remote Monitored Systems revealed P2F had received a conditional order for one million face masks per month for a period of one year from 1 January 2021, subject to the masks successfully completing antiviral and other performance tests and receiving the necessary PPE certifications.
The order is also conditional on the buyer entering into sales contracts to sell a similar volume of masks per month.
Pharm 2 Farm is a wholly-owned RMS subsidiary since the acquisition from Braveheart Investment Group PLC (LON:BRH) was completed in early November.